BSE filing, NSE: APLLTD. Summary written from the filing by ALFA Finder's alert engine.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹788.00
- Market cap
- ₹15,489 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 22.3×Sector 46.5×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Board Meeting Date
Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.26 Cr
Alembic Pharmaceuticals' subsidiary, Alembic Global Holding SA, incorporated a new wholly-owned subsidiary, Alvesta Pharmaceuticals FZCO, in the UAE for Rs. 0.26 Crore.
- Value
- ₹0.26 Cr
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.23 Cr
Alembic Pharmaceuticals' wholly-owned subsidiary, Alembic Global Holding SA, incorporated a new step-down subsidiary, Alvesta Pharmaceuticals FZCO, in Dubai for AED 1 Lakh (approx. ₹0.23 Crore).
- Value
- ₹0.23 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP. This drug is therapeutically equivalent to the reference product Ciprodex Otic Suspension.
Alembic Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Other credit rating announcements
All →GSPL Transmission Credit Rating
CARE Ratings assigned GSPL Transmission a CARE AA+ rating on bank facilities with a stable outlook. The rating cites nil debt and strong liquidity.
Meghmani Organics Credit Rating
India Ratings assigned Meghmani Organics' bank loan facilities of INR 11,000 million a rating of IND A/Stable/IND A1. The filing encloses the rating letter and a facilities breakup.
JSW Cement Credit Rating
CRISIL reaffirmed JSW Cement's long-term rating at AA-/Stable and its short-term ratings at A1+. No new borrowing or fund raise is announced.
Tejas Networks Credit Rating
ICRA reaffirmed Tejas Networks' [ICRA]A+(Stable) long-term rating and [ICRA]A1+ short-term rating. The rating covers Rs.6,000 Crore of credit facilities and a Rs.500 Crore CP programme.
HDB Financial Services Credit Rating
CARE Ratings reaffirmed HDB Financial Services' AAA rating with Stable outlook across its debt instruments. Its A1+ short-term rating was also reaffirmed.
Asian Energy Services Credit Rating
Asian Energy Services Limited disclosed that CRISIL maintained its 'Watch Developing' rating on INR 317.5 Crore of bank facilities. The watch continues pending final Ministry of Petroleum approval for the merger of its parent, Oilmax Energy.